We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
The Role of IL-23 Inhibitors in Crohn's Disease.
- Authors
Fanizza, Jacopo; D'Amico, Ferdinando; Lusetti, Francesca; Fasulo, Ernesto; Allocca, Mariangela; Furfaro, Federica; Zilli, Alessandra; Parigi, Tommaso Lorenzo; Radice, Simona; Peyrin-Biroulet, Laurent; Danese, Silvio; Fiorino, Gionata
- Abstract
Promoting a Th17 pathogenic response, the interleukin (IL)-23 pathway is crucial in the pathophysiology of inflammatory bowel disease (IBD). With a favorable safety profile, ustekinumab, a monoclonal antibody targeting the shared p40 component of IL-12/23, is currently approved for the treatment of IBD in patients with disease refractory to corticosteroids and biologic drugs. Risankizumab, mirikizumab, and guselkumab are specific IL-23p19 antagonists tested for the treatment of Crohn's disease (CD). However, only risankizumab currently has been approved for its treatment. Trials with guselkumab and mirikizumab are currently ongoing, with promising preliminary efficacy and safety results. In this review, we provide a summary of the current knowledge about selective IL-23 inhibitors, focusing on their positioning in the therapeutic algorithm of patients with moderate to severe CD.
- Subjects
CROHN'S disease; INFLAMMATORY bowel diseases; MONOCLONAL antibodies
- Publication
Journal of Clinical Medicine, 2024, Vol 13, Issue 1, p224
- ISSN
2077-0383
- Publication type
Article
- DOI
10.3390/jcm13010224